Pharmaceuticals News

FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...

In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patientsDenifanstat showed progressive...

Hummingbird Bioscience announced that the first patient has been dosed in Phase II trial of HMBD-001 and cetuximab in advanced squamous cell cancers.

New data suggest that givinostat treatment may slow the decline of upper limb function in boys with Duchenne muscular dystrophy compared with modelled external comparator disease trajectories derived...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE30 SEPTEMBER 2026 at 9.05 EEST         Orion Corporation completed share acquisitions ...

ORION OYJ        PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT30.9.2026 KLO 9.05          Orion Oyj:n omien osakkeiden hankinta päättynyt Orion Oyj:n 27.8.2026 tiedottama...

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES30/09/2026 at 09.00 EEST         Orion Corporation: Acquisition of own shares during week 40, 2026 The share buybacks form...

ORION OYJ        PÖRSSITIEDOTE – MUUTOKSET OMIEN OSAKKEIDEN OMISTUKSESSA        30.09.2026 KLO 09.00          Orion Oyj: Omien osakkeiden hankinta viikolla 40/2026 Osakkeiden takaisinostot ovat...

Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie,...

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the...